TY - JOUR
T1 - Decoy Receptor 3 Expression Is AssociatedWith Wild-Type EGFR Status, PoorDifferentiation of Tumor, and UnfavorablePatient Outcome
T2 - ClinicopathologicAnalyses of 461 Lung Adenocarcinomas
AU - Chang, d. Wei Chin
AU - Yeh, Yi Chen
AU - Ho, Hsiang Ling
AU - Hsieh, Shie Liang
AU - Chou, Teh Ying
N1 - Funding Information:
This work was partially funded by grants V106D27-001-MY2-2, V107C-001, and VTA107-V1-3-1 from Taipei Veterans General Hospital and grant MOST105-2320-B-075-003-MY3-1 from the Ministry of Science and Technology.
Publisher Copyright:
© 2019 Oxford University Press. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Objectives The role of decoy receptor 3 (DcR3) in lung cancer, particularlyadenocarcinoma, has not been well studied. In this study, weaim to investigate the expression profile and theclinicopathologic implications of DcR3 expression in lungadenocarcinoma. Methods Immunohistochemistry was used to examine DcR3 expression in461 lung adenocarcinomas. The differences in DcR3 expressionamong the various histopathologic patterns were analyzed. Therelationship between DcR3 expression and clinicopathologicparameters, including epidermal growth factor receptor (EGFR)mutation, was also investigated. Results DcR3 expression was more frequently expressed in solid,micropapillary, and acinar patterns (P < .0001) and in tumorswith wild-type EGFR status (P = .018). In addition, DcR3expression portends a less favorable disease-free survival instage I patients (P = .012). Conclusions The expression of DcR3 might be involved in the differentiationand progression of lung adenocarcinoma. Therefore, DcR3 maybe applied clinically for prediction of tumor progression in stageI lung adenocarcinoma.
AB - Objectives The role of decoy receptor 3 (DcR3) in lung cancer, particularlyadenocarcinoma, has not been well studied. In this study, weaim to investigate the expression profile and theclinicopathologic implications of DcR3 expression in lungadenocarcinoma. Methods Immunohistochemistry was used to examine DcR3 expression in461 lung adenocarcinomas. The differences in DcR3 expressionamong the various histopathologic patterns were analyzed. Therelationship between DcR3 expression and clinicopathologicparameters, including epidermal growth factor receptor (EGFR)mutation, was also investigated. Results DcR3 expression was more frequently expressed in solid,micropapillary, and acinar patterns (P < .0001) and in tumorswith wild-type EGFR status (P = .018). In addition, DcR3expression portends a less favorable disease-free survival instage I patients (P = .012). Conclusions The expression of DcR3 might be involved in the differentiationand progression of lung adenocarcinoma. Therefore, DcR3 maybe applied clinically for prediction of tumor progression in stageI lung adenocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85069273408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069273408&partnerID=8YFLogxK
U2 - 10.1093/ajcp/aqz035
DO - 10.1093/ajcp/aqz035
M3 - Article
C2 - 31077284
AN - SCOPUS:85069273408
SN - 0002-9173
VL - 152
SP - 207
EP - 216
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 2
ER -
